Lava Therapeutics N.V. (NQ: LVTX )
2.030 -0.070 (-3.33%) Streaming Delayed Price Updated: 11:16 AM EDT, Jun 7, 2023 Add to My Watchlist
All News about Lava Therapeutics N.V.
Why Guidewire Software Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Friday's Mid-Day Session
June 02, 2023
Gainers MultiMetaVerse Holdings Limited (NASDAQ: MMV) gained 236% to $3.1592 after the company announced it signed a non-binding term sheet to acquire an equity stake in Taomee group.
Gainers Better Choice Company Inc. (NASDAQ: BTTR) shares rose 37% to $0.4522 in pre-market trading. Better Choice said it has selected Re:Amaze to assist in customer retention and acquisition for its...
LAVA Announces Annual Meeting of Shareholders
May 30, 2023
Why Netcapital Shares Are Trading Lower By Over 33%? Here Are 50 Stocks Moving In Wednesday's Mid-Day Session
December 14, 2022
Gainers Crown ElectroKinetics Corp. (NASDAQ: CRKN) shares rose 153% to $0.3325 after gaining 14% on Tuesday. Crown ElectroKinetics, last month, posted a Q3 loss of $0.18 per share.
Why Vallon Pharmaceuticals Shares Are Trading Higher By Over 150%; Here Are 29 Stocks Moving Premarket
December 14, 2022
Gainers Vallon Pharmaceuticals, Inc. (NASDAQ: VLON) shares rose 150.9% to $0.6313 in pre-market trading after the company entered into a definitive merger agreement with GRI Bio.
LAVA Therapeutics Announces Updated Data from the Phase 1/2a Clinical Trial of LAVA-051 at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition
December 10, 2022
Poster presentation to include initial data from subcutaneous administration and updates on intravenous dosing-cohorts
Benzinga's Top Ratings Upgrades, Downgrades For October 25, 2022
October 25, 2022
Snap To Surge Around 20%? Here Are 5 Other Price Target Changes For Tuesday
September 27, 2022
Piper Sandler raised Snap Inc. (NYSE: SNAP) price target from $11 to $12. Piper Sandler analyst Thomas Champion maintained the stock with a Neutral. Snap shares fell 1.4% to close at $10.18 on Monday.
LAVA Therapeutics (NASDAQ: LVTX) Enters into Global Licensing Agreement with Seagen (NASDAQ: SGEN) to Develop and Commercialize LAVA-1223
September 26, 2022
LAVA Therapeutics N.V. (NASDAQ: LVTX) is engaged as a clinical-stage oncology company, which is focused on the research and development
Via Spotlight Growth
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following